Join
Live feed
·
PRReleasevia Quantisnow
AgomAb Therapeutics NV logo

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
AGMB· AgomAb Therapeutics NV
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AGMB (AgomAb Therapeutics NV) and more on Quantisnow.